First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples